ARAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Accuray Inc (ARAY) is not a strong buy at the moment for a beginner investor with a long-term horizon. Despite a recent price surge, the company's financial performance is significantly declining, and there are no strong positive catalysts or trading signals to support a buy decision. Holding off on this investment is advisable until there are clearer signs of financial recovery or stronger growth potential.
The MACD histogram is positive and expanding, suggesting bullish momentum. The RSI is neutral at 58.644, indicating no overbought or oversold conditions. The stock is trading near its R1 resistance level of 0.424, with key support at 0.385. Moving averages are converging, showing no clear trend.
Appointment of Paul Miele as Chief Commercial Officer, who has a strong track record in driving sales growth in the medical technology sector. Focus on enhancing cancer treatment innovation and global commercialization strategy.
Significant financial decline in Q2 2026, with revenue down 11.99% YoY, net income down 642.77% YoY, and EPS down 650% YoY. BTIG lowered the price target to $2 from $4 due to sales and EBITDA cuts driven by geopolitical pressures.
In Q2 2026, revenue dropped to $102.24M (-11.99% YoY), net income fell to -$13.77M (-642.77% YoY), EPS declined to -0.11 (-650% YoY), and gross margin decreased to 23.19 (-34.82% YoY).
BTIG maintains a Buy rating but lowered the price target to $2 from $4, citing geopolitical pressures and reduced sales and EBITDA expectations.
